815 material Form 8-K filings that 659 companies we cover made with the SEC in March 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Dawson Geophysical reported unaudited fourth-quarter and full-year 2025 results. Q4 revenue rose 72% to $27.0 million and the company posted net income of $0.6 million, compared with a net loss of $0.8 million a year earlier. Full-year net loss narrowed to $1.9 million from $4.1 million, though revenue grew only 2%. The filing also says Wilks Brothers and its affiliates, which control about 80% of the stock, are in discussions on possible transactions with the company, with no definitive agreement reached.
Q4 2025 total revenue was $27.0 million, up 72% from $15.6 million; Q4 net income was $0.6 million, or $0.02 per share, versus a net loss of $0.8 million in Q4 2024
Full-year 2025 revenue was $75.6 million, up 2% from $74.2 million; net loss was $1.9 million, or $0.06 per share, compared with $4.1 million, or $0.13 per share, in 2024
Wilks Brothers, LLC and affiliates control about 80% of common stock; discussions on possible transactions have no guarantee of a definitive agreement, and $528,000 of related expenses were incurred in Q4 2025
Cash from operations was $14.0 million in 2025; cash rose to $4.9 million at December 31, 2025, and the 2026 capital budget is $3 million
DiaMedica Therapeutics reported full-year 2025 results showing a wider net loss of $32.8 million, or $0.70 per share, compared with $24.4 million, or $0.60 per share, in 2024, as research and development and general and administrative costs rose. The company ended 2025 with $59.9 million in cash and short-term investments, which it says will fund operations through the second half of 2027, after share sales in July 2025 and under its at-the-market program.
Net loss for 2025 was $32.8 million, or $0.70 per share, versus $24.4 million, or $0.60 per share, in 2024.
Research and development expenses rose to $24.6 million from $19.1 million, driven mainly by the ReMEDy2 trial and its global expansion.
General and administrative expenses rose to $9.8 million from $7.6 million, including higher share-based compensation.
Cash and short-term investments were $59.9 million at December 31, 2025, up from $44.1 million a year earlier.
TherapeuticsMD reported full-year 2025 results in a press release furnished on Form 8-K. The net loss from continuing operations narrowed to $0.7 million from $2.3 million in 2024, as license revenue rose 71.6% to $3.0 million and operating expenses fell 5.9% to $7.4 million. The company said it continues to explore strategic alternatives, including a possible acquisition, merger or sale of assets, but has set no timetable and gave no assurance of a transaction.
Net loss from continuing operations was $(0.7) million, or $(0.06) per share, versus $(2.3) million, or $(0.20) per share, in 2024.
License revenue, primarily from the Mayne License Agreement, was $3.0 million, up from $1.8 million in 2024.
Total operating expenses were $7.4 million, down $0.5 million, mainly due to lower impairment charges.
Cash and cash equivalents were $7.5 million as of December 31, 2025.
Progress Software reported fiscal first-quarter 2026 revenue of $248 million, up 4% from a year earlier (2% on a constant currency basis), with GAAP diluted earnings per share of $0.53 versus $0.24. The company changed its full-year 2026 outlook in mixed directions: GAAP diluted EPS guidance was lowered to $1.71 to $1.87 from $1.74 to $1.91, while non-GAAP diluted EPS guidance was raised to $5.91 to $6.03 from $5.82 to $5.96.
Q1 revenue $248 million, up 4% year over year; GAAP diluted EPS $0.53 versus $0.24; non-GAAP diluted EPS $1.60 versus $1.31
Fiscal 2026 revenue guidance $988 million to $1,000 million, with the low end raised from $986 million
Fiscal 2026 GAAP diluted EPS guidance cut to $1.71 to $1.87; non-GAAP diluted EPS guidance raised to $5.91 to $6.03
Second-quarter 2026 revenue guidance $240 million to $246 million; GAAP diluted EPS $0.35 to $0.41
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.